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complication rates. Cardiac and vascular complications remain the major concern for
LAA closure.
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Background: Paravalvular leaks (PVL)affect up to 17% of all surgically implanted
prosthetic valves. Reoperation is associated with high morbidity and mortality.
Transcatheter transapical (TA) closure is an emerging alternative for selected high-risk
patients with PVL. The aim of this study is to compare the in-hospital outcomes of
patients who underwent surgery and TA-closure for PVL in our single-center
experience.
Methods: From October 2000 and June 2013, 136 patients with PVL were treated in
our Institution: 122 patients (89.7%%) underwent surgery (68% mitral-PVL; 32%
aortic-PVL) and 14 patients (10.3%) underwent TA closure (all the pts had mitral
PVL; 1 case had combined mitral and aortic PVLs). All the TA procedures were
performed under general anesthesia in a hybrid operative room: in all but 1 case an
Amplatzer Vascular Plug III device was utilized.
Results: Baseline features of the patients were comparable in terms of age (p¼0.9),
associated coronary artery disease (p¼0.6), chronic renal failure (p¼0.2), previous
endocarditis (p¼0.08), concomitant atrial ﬁbrillation (p¼0.4), while COPD was more
prevalent in TA group (P¼0.002). Log-EuroScore was 1511% and 198% in
surgical and TA group respectively (p¼0.03). Most of the patients were in NYHA
class III-IV (60% Vs 78%; p¼0.1); 41% of surgical patients and 86% of TA patients
were at their second of more reoperation (p¼0.0001). Procedural success in TA group
was 93% (1 conversion to surgery because of the dislocation of the device). In-
hospital mortality was 10.6% in surgical group (all cardiac-related) and 0% in TA
group (p¼0.08). Mean LOS was 19 days for surgery and 9 days for TA (p¼0.1). All
the patients had less than moderate residual valve regurgitation after the procedure.
Surgical treatment was identiﬁed as risk factor for in-hospital death at multivariate
analysis (OR 1.6; p¼0.04).
Conclusions: Transcatheter TA approach is a safe and effective therapeutic option in
selected high-risk patients with PVL and it is associated with reduced risk of hospital
mortality than surgical treatment, in spite of higher predicted risk. Further studies are
needed to determine the long-term results of the two procedures.
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Background: Baroreceptors and sympathetic nerve ﬁbers are localized in or near the
bifurcation area of the main PA. We previously demonstrated that PADN completely
abolished the experimentally elevated PA pressure responses to occlusion of the left
interlobar pulmonary artery.
Methods: Out of a total of 21 patients with IPAH, 13 patients received the PADN
procedure, the other 8 patients who refused the PADN procedure were assigned to theJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrcontrol group. PADN was performed at the bifurcation of the main PA, and at the
ostial right and left PA. Serial echocardiography, right heart catheterization, and a
6-minute walk test (6MWT) were performed. The primary endpoints were the change
of pulmonary artery pressure (PAP), tricuspid excursion (Tei) index, and 6MWT at
3-months follow-up.
Results: Compared with the control group, at 3 months follow-up, the patients who
underwent the PADN procedure showed signiﬁcant reduction of mean PAP (from
555 mmHg to 365 mmHg, p<0.01), signiﬁcant improvement of the 6MWT (from
32421 m to 49138 m, p<0.006) and of the Tei index (from 0.30.04 to
0.500.04, p<0.001).
Conclusions: We report for the ﬁrst time the effect of PADN on functional capacity
and hemodynamics in patients with IPAH not responding optimally to medical
therapy. Further randomized study is required to conﬁrm the efﬁcacy of PADN.
(chiCTR-ONC-12002085)
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Background: Vitamin K antagonists (VKA) such as warfarin are recommended in the
Group 1 Pulmonary Hypertension (PH) cohort based on poor quality evidence.
Among proposed mechanisms of beneﬁt is that endothelial dysfunction present in
patients with Pulmonary Arterial Hypertension (PAH) causes abnormalities in coag-
ulation factors, antithrombotic factors and ﬁbrinolytic system, which ﬁnally leads to
a prothrombotic state in patients with PAH. This is supported by the fact that laminar
thrombus has been found in the typical plexiform lesions that affects small muscular
arteries and supernumerary pulmonary arteries. However, unlike Chronic Thrombo-
embolic Pulmonary Hypertension (CTEPH) the evidence base in support of anti-
coagulation in patients with PAH remains weak. We normally rely on non-invasive
tests such as CT Pulmonary Angiography (CTPA), Ventilation-Perfusion Scan (VQ),
MRI and conventional pulmonary angiography to differentiate between CTEPH and
PAH. What would happen if despite using these modalities, we are misclassifying
patients with distal diffuse CTEPH as PAH?
Methods: 11 consecutive patients diagnosed with PAH were enrolled in an ethics
approved study to undergo OCT imaging of their pulmonary arteries following routine
right heart catheterisation (RHC) at the Royal Free London NHS Foundation Trust in
London. A 6Fr Guidant Swan-Ganz type Balloon Catheter was situated and wedged
into a subsegmental pulmonary vessel. Through this catheter a LightLabImageWire
Cardiovascular imaging wire was passed into the distal vessel. An automated pullback
of the vessel was obtained the data transferred and stored on a workstation for off-line
analysis. Previous studies of these patients to rule out thromboembolic disease (CTPA,
VQ and conventional pulmonary angiography) were checked and reviewed again by
two independent and blinded nuclear and radiology consultants.
Results: 4 of these 11 patients were found to have thrombus and/or webs (indicative
of recanalised thrombus) suggesting CTEPH.
Conclusions: OCT imaging of the pulmonary vascular tree allows for the detection of
CTEPH patients previously diagnosed as PAH. These novel ﬁndings, are potentially
important as the role of VKA in PAH is under discussion.
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Background: Adequate septal rim is an important factor for device closure of atrial
septal defect (ASD). As little is known about the procedural completion in ASD
patients with multiple rim deﬁciencies, we aimed to evaluate the validity of device
closure for these patients.
Methods: Between September 2007 andMay 2013, 372 consecutive adult ASDpatients
(mean 54  17 years) were attempted for device closure using Amplatzer septal
occluder. According to TEE ﬁndings, rim deﬁciency (<5 mm) was deﬁned as supero-
anterior, infero-anterior, supero-posterior, and infero-posterior rim deﬁciencies. Patients
were divided into three groups: "sufﬁcient" group, sufﬁcient rim (n¼77); "single" group,
1 rim deﬁciency including 9 patients with infero-posterior rim deﬁciency (n¼268);
"multiple" group, more than 1 rim deﬁciencies (n¼27). Procedural success was deﬁned
as device implantation with no in-hospital serious adverse events.acts/POSTER/Non-valvular Structural Heart Disease B209
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"single" group (29 mm, 16 mm, 19 mm, p<0.01). Procedural success rate was 98%
with no in-hospital death. One cardiac erosion occurred in "single" group and 1 device
embolization occurred in "multiple" group. In 6 patients, stable device deployment
was not achieved. Although procedural success rate in "multiple" group was signiﬁ-
cantly lower than "sufﬁcient" or "single" group, >80% of patients having multiple rim
deﬁciencies completed the procedure (Figure).Conclusions: Even for ASD patients with multiple rim deﬁciencies, device closure
has the validity to be considered as an initial therapeutic option.
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Background: The objective of our study was to describe the initial worldwide
experience with the AmuletTM, the second generation of the AmplatzerTM Cardiac
Plug, for percutaneous left atrial appendage (LAA) closure
Methods: Between July 2012 and May 2013, all patients undergoing LAA closure
using the AmuletTM were included in the study. The AmuletTM has been designed
to facilitate the implantation process and minimize complications because of stra-
tegic modiﬁcations without changing the main design of the ﬁrst generation
AmplatzerTM Cardiac Plug. Indication for LAA closure was based on a formal
contraindication for oral anticoagulation. All procedures were done under general
anesthesia and transesophageal echocardiography (TEE) guidance. Transthoracic
echocardiography was performed 24 hours after the procedure to rule out peri-
procedural complications. Further clinical follow-up and TEE was done at 1 to 3
months.
Results: Twenty one patients (mean age 748; 61.5% males) with a CHADS2
score of 31.45 were included in the study. Four patients (19%) presented with
complex chicken-wing LAA anatomies with an early signiﬁcant (100o) bend.
The AmuletTM was successfully implanted in all patients except one, which
presented with a very small LAA. The mean size of the device was 23.84.3 mm.
No device embolization, procedure-related strokes or pericardial effusions were
documented. One patient developed a LAA thrombus during the procedure related
to the delivery sheath that was successfully trapped behind the device without
sequelae. Clinical and follow-up TEE at 1 - 3 months was available in 17 patients
(81%). During follow up, one patient (4.8%) had a thrombus at the atrial surface
of the AmuletTM. However, the same patient also had a larger thrombus on the
left atrial surface of an AmplatzerTM atrial septal occluder implanted on the same
day of his LAA occlusion. None of the patients presented with any clinical events
and all of them showed complete LAA sealing without any degree of residual
shunt.
Conclusions: In this initial series, the AmuletTM showed good performance in terms
of efﬁcacy and safety as depicted by the successful implantation in almost all patients
and the absence of procedural complications.B210 JACC Vol 62/18/Suppl B j October 27–November 1,TCT-687
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Background: Accurate measurement of the left atrial appendage (LAA) neck and
depth are important for correct sizing and safe placement of LAA closure devices.
However, our experience suggests that LAA measurements derived from 2D TEE do
not consistently predict closure device size, and do not consistently correlate with
LAA measurements derived from LAA angiography.
Methods: Two-dimensional TEE measurements of the isthmus and neck of the LAA
were performed in orthogonal planes at 0, 45, 90, and 135 degrees. During LAA
angiography, the LAA neck was measured in the right anterior oblique (RAO) caudal
projection and the depth in the RAO cranial plane. The diameter of a 6 Fr pigtail
catheter was used as standard reference for the angiographic measurements.
Results: 43 patients underwent LAAO in the period February 2010 to May 2013.
LAA closure was performed with a Watchman device in 29 patients (67%), a Coherex
device in 11 patients (26%), and an Amplatzer plug in the remaining 3 patients. 9
procedures had to be abandoned, 4 because of complications, and 5 because of
unsuitable LAA anatomy. On angiography, the mean LAA depth was 34 mm (range,
16-53 mm), whereas the average LAA isthmus length was 21 mm (range, 8-38 mm).
Conversely, on 2D-TEE mean LAA depth was 28 mm (range, 15-44 mm), whereas
the average isthmus length was 20 mm (range, 12-33 mm). The mean discrepancy
between the maximal LAA neck measurements derived from LAA angiography and
2D-TEE was 0.8 mm, whereas the discrepancy between the measurements of the
depth was 3 mm, with TEE undersizing the LAA dimensions compared to angiog-
raphy. By contrast, 2D-TEE overestimated the LAA neck dimensions compared to
angiography in unsuccessful procedures, by an average of 1.2 mm. The average
discrepancy between the maximal LAA neck length measured by 2D-TEE and LAA
angiography and the diameter of the implanted device was 5 mm and 4 mm,
respectively.
Conclusions: TEE systematically underestimates LAA dimensions compared to
angiography. By contrast, in unsuccessful procedures, TEE oversized the LAA neck
compared to angiography. Implanted device diameter is on average 5 mm and 4 mm
greater than the LAA neck length derived from TEE and angiography, respectively.
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Background: Amulet Device (St Jude Medical, Minneapolis, MN, USA) is a new
self-expanding device speciﬁcally designed for LAA closure. It was designed to
facilitate the implantation process and minimize procedural or device-related
complications.
Methods: The Amulet Device was implanted in 17 patients with non-valvular atrial
ﬁbrillation (AF) and high stroke risk. All patients received clopidogrel 75 mg for 3
months and aspirin for minimum 6 months after the implantation. Transesophageal
echocardiography (TEE) was performed for all patients as pre-procedural assessment
for LAA morphology. Sizing of LAA landing zone was based on ﬂuoroscopic and
TEE measurements. Clinical data were obtained at baseline, during the procedure, at
discharge and at 30 days.
Results: All devices were implanted successfully via left femoral vein under ﬂuoro-
scopic and TEE guidance. Transseptal puncture was performed in 14 patients.
Implantation was performed via concomitant patent foramen ovale (PFO) in 3
patients. All device deployment fulﬁlled the recommended criteria. Device size ranged
from 20mm to 31mm. For each case a 12 Fr or 14 Fr delivery sheath was used
depending on the compatibility with the size of the device. Full recapture and partial
recapture was performed in 1 case and 3 cases respectively. There was 1 procedural-
related pericardial effusion that was successfully managed with pericardial drainage.
There was no device embolization. The mean length of stay was 2.12 days. At 30
days, there were no deaths, strokes and no additional bleeding complications. TEE
repeated at 30 days showed no device-related thrombus or pericardial effusion. 2 out
of the 17 patients showed minimal peri-device ﬂow (width smaller than 2mm).
Conclusions: The Amulet device, which has new novel features in design as
compared with the ﬁrst generation ACP, is a feasible option for LAA closure with
good short-term outcome at 30 days. Potential advantages over the ﬁrst generation
ACP include ease of device preparation, better ﬁt to different LAA anatomy and
sealing of LAA ostium, facilitation of device recapture and device positioning, more
stable anchor and minimized risk of thrombus formation on surface of the device.2013 j TCT Abstracts/POSTER/Non-valvular Structural Heart Disease
